Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bliss Gvs Pharma Limited ( (IN:BLISSGVS) ) has issued an update.
Bliss GVS Pharma Limited has strengthened its board by appointing Vijayanarayanan Mahadevan and Deepak Rameshchandra Shah as additional non-executive independent directors for a five-year term starting April 3, 2026. Both appointees bring extensive chartered accountancy, finance, taxation, and audit expertise, and the board has approved a postal ballot to seek shareholder approval for their appointments, signaling a focus on enhanced governance and financial oversight.
Mahadevan has over 35 years of global finance leadership across multinationals, known for turning around loss-making businesses and leading restructuring and regulatory initiatives. Shah, with more than 36 years of experience and several independent directorships in listed companies, is a prominent taxation and audit expert, reinforcing the company’s governance framework and board independence for long-term strategic and compliance needs.
More about Bliss Gvs Pharma Limited
Bliss GVS Pharma Limited operates in the pharmaceutical industry, focusing on the development and manufacture of healthcare products. The company serves domestic and international markets and is listed on major Indian stock exchanges, positioning it within the regulated, disclosure-heavy environment for listed pharma players.
Average Trading Volume: 345,342
Technical Sentiment Signal: Buy
Current Market Cap: 24.79B INR
Learn more about BLISSGVS stock on TipRanks’ Stock Analysis page.